Metformin exerts multitarget antileukemia activity in JAK2(V617F)-positive myeloproliferative neoplasms

The recurrent gain-of-function JAK2(V617F) mutation confers growth factor-independent proliferation for hematopoietic cells and is a major contributor to the pathogenesis of myeloproliferative neoplasms (MPN). The lack of complete response in most patients treated with the JAK1/2 inhibitor ruxolitin...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cell Death Dis
Huvudupphovsmän: Machado-Neto, João Agostinho, Fenerich, Bruna Alves, Scopim-Ribeiro, Renata, Eide, Christopher A., Coelho-Silva, Juan Luiz, Dechandt, Carlos Roberto Porto, Fernandes, Jaqueline Cristina, Rodrigues Alves, Ana Paula Nunes, Scheucher, Priscila Santos, Simões, Belinda Pinto, Alberici, Luciane Carla, de Figueiredo Pontes, Lorena Lôbo, Tognon, Cristina E., Druker, Brian J., Rego, Eduardo Magalhães, Traina, Fabiola
Materialtyp: Artigo
Språk:Inglês
Publicerad: Nature Publishing Group UK 2018
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833553/
https://ncbi.nlm.nih.gov/pubmed/29472557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-017-0256-4
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk